Line 1: |
Line 1: |
− | '''Table 1 - Gene fusions reported in Ph-like B-ALL and other new B-ALL molecular subtypes (Literature Review)'''. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. | + | '''Table 1 - Prevalence and prognosis of B-ALL genomic abnormalities in the pediatric and adult population for all categories reported to date.''' Of the Ph-like category, only CRLF2 and ABL1-class rearrangements are indicated. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. All percentages are approximate. |
| + | {| class="wikitable" |
| + | | |
| + | | colspan="2" |'''Percentage of B-ALL Cases''' |
| + | | |
| + | |- |
| + | |'''Genomic abnormality''' |
| + | |'''Pediatric''' |
| + | |'''Adult''' |
| + | |'''Prognosis''' |
| + | |- |
| + | |t(12;21)(p13;q22); [[ETV6]]-[[RUNX1]]* |
| + | |25% |
| + | |3% |
| + | |Favorable |
| + | |- |
| + | |Hyperdiploidy* |
| + | |25% |
| + | |5-7% |
| + | |Favorable |
| + | |- |
| + | |t(9;22)(q34;q11.2); [[BCR]]-[[ABL1]]* |
| + | |2-4% |
| + | |25-30% |
| + | |Poor (outcome may improve with TKI) |
| + | |- |
| + | |[[CRLF2]] (PAR1, Xp22.33/Yp11.2) (Ph-like) |
| + | |5% |
| + | |20% |
| + | |Poor |
| + | |- |
| + | |ABL-Class fusions (Ph-like) |
| + | |3-5% |
| + | |2-3% |
| + | |Poor (outcome may improve with TKI) |
| + | |- |
| + | |[[KMT2A Partner Genes|KMT2A]] (11q23) rearrangements* |
| + | |5% |
| + | |10% |
| + | |Poor |
| + | |- |
| + | |t(1;19)(q23;p13.3); [[TCF3]]-[[PBX1]]* |
| + | |5% |
| + | |3% |
| + | |Favorable |
| + | |- |
| + | |[[TCF3]] (19p13.3) rearrangements (excluding [[ZNF384]]) |
| + | |>1% |
| + | |>1% |
| + | |Extremely Poor |
| + | |- |
| + | |Hypodiploidy* |
| + | |1-2% |
| + | |15% |
| + | |Poor |
| + | |- |
| + | |dic(9;12)(p13;p13) |
| + | |1% |
| + | |Rare |
| + | |Favorable |
| + | |- |
| + | |dic(9:20)(p13;q11) |
| + | |2% |
| + | |1% |
| + | |Favorable |
| + | |- |
| + | |t(4;14)(q35.2;q32); [[IGH-DUX4|IGH/DUX4]] |
| + | |5-9% |
| + | |5% |
| + | |Favorable |
| + | |- |
| + | |t(5;14)(q31.1;q32.1); [[IGH]]/[[IL3]]* |
| + | |1% |
| + | |1% |
| + | |Unknown |
| + | |- |
| + | |[[ZNF384]] (12p13.31) rearrangements |
| + | |1-5% |
| + | |2-7% |
| + | |Favorable |
| + | |- |
| + | |iAMP21 ([[RUNX1]])* |
| + | |2% |
| + | |Rare |
| + | |Poor |
| + | |- |
| + | |[[IKZF1]] deletions |
| + | |15-20% |
| + | |25-30% |
| + | |Poor except in combination with ERG del |
| + | |} |
| + | <nowiki>*</nowiki>indicates 2016 WHO entities including provisional categories. |
| + | |
| + | |
| + | '''Table 2 - Gene fusions reported in Ph-like B-ALL and other new B-ALL molecular subtypes (Literature Review)'''. Table derived from Akkari et al., 2020 [PMID 32302940] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Subtype''' | | |'''Subtype''' |